News & Publications

2018
11/21

Evotec and Immuneering to collaborate on artificial intelligence (“AI”) driven ligand identification for rare hereditary metabolic diseases

COMBINATION OF CUTTING-EDGE IPSC AND AI TECHNOLOGIES CREATES OPPORTUNITY TO DISCOVER NOVEL METABOLIC LIGANDS TO ACCELERATE DRUG DISCOVERY IN RARE METABOLIC DISEASES

Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a research collaboration with Immuneering Corporation (“Immuneering”), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases.


2018
06/18

The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer’s disease

Cambridge, MA and London, 18 June 2018 – The Dementia Discovery Fund (“DDF”) and Immuneering Corporation (“Immuneering”) today announce they have entered into a joint research collaboration to identify novel drug targets and drug candidates for Alzheimer’s disease.  As part of the collaboration, the DDF will invest $1.3 million for the use of Immuneering’s proprietary computational drug discovery platform to analyse publicly available data sets from Alzheimer’s disease patients.  The goal of the collaboration is to identify clinically identifiable, mechanistically linked subpopulations within Alzheimer’s disease and generate new molecular entities (NMEs) that will ultimately lead to new medicines to treat Alzheimer’s disease.


2018
06/11

Immuneering CEO Ben Zeskind to speak at 4th Cancer Cachexia Conference

June 11th, 2018 — Immuneering’s CEO (Ben Zeskind) is scheduled to present an invited talk entitled “Data-driven identification and optimization of new medicines for cancer cachexia” at the 4th Cancer Cachexia Conference on Sunday, September 16 2018 in Philadelphia, organized by the Cancer Cachexia Society. Immuneering is also proud to sponsor this important event, and to be a part of community of researchers working to develop effective treatments for this significant unmet need.


2018
05/30

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone

DOI: https://doi.org/10.1016/j.ensci.2018.05.006

eNeurologicalSci – May 30, 2018


2018
05/21

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

DOI:10.1186/s13024-018-0259-3

Molecular Neurodegeneration – May 21, 2018


2018
05/15

Structural Changes Due to Antagonist Binding in Ligand Binding Pocket of Androgen Receptor Elucidated through Molecular Dynamics Simulations

doi:10.3389/fphar.2018.00492

Frontiers in Pharmacology – May 15, 2018


2018
04/18

Metastasis: Leveraging transcriptomics to identify potential therapeutics

Poster Presentation – AACR annual meeting 2018


2018
04/16

Cachexia: Leveraging transcriptomics to identify potential therapeutics

Poster Presentation – AACR annual meeting 2018


2018
04/09

Loss of the Sigma-1 receptor disrupts pridopidine-induced gene expression

Poster Presentation – AAN 2018


2018
03/15

Integrity, standards, and QC-related issues with big-data in pre-clinical drug discovery

doi:10.1016/j.bcp.2018.03.014

Biochemical Pharmacology – March 15, 2018


MORE ENTRIES